Literature DB >> 11520836

Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial.

S Sundar1, G Agrawal, M Rai, M K Makharia, H W Murray.   

Abstract

OBJECTIVE: To test short course, low dose liposomal amphotericin B as single or daily infusion treatment in Indian visceral leishmaniasis (kala-azar).
DESIGN: Randomised, open label study.
SETTING: Inpatient unit for leishmaniasis in Bihar, India. PARTICIPANTS: 91 adults and children with splenic aspirate positive for infection.
INTERVENTIONS: Total dose of 5 mg/kg of liposomal amphotericin B given as a single infusion (n=46) or as once daily infusions of 1 mg/kg for five days (n=45). MAIN OUTCOME MEASURES: Clinical and parasitological cure assessed 14 days after treatment and long term definitive cure (healthy, no relapse) at six months.
RESULTS: All but one person in each group had an initial apparent cure. During six months of follow up, three patients in the single dose group and two in the five dose group relapsed. Complete response (definitive cure) was therefore achieved in 84 of 91 subjects (92%): 42 of 46 patients in the single dose group (91%, 95% confidence interval 79% to 98%) and 42 of 45 in the five dose group (93%, 82% to 99%). Response rates in the two groups were not significantly different.
CONCLUSION: Low dose liposomal amphotericin B (5 mg/kg), given either as a five day course or as a single infusion, seems to be effective for visceral leishmaniasis and warrants further testing.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11520836      PMCID: PMC37549          DOI: 10.1136/bmj.323.7310.419

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  16 in total

Review 1.  Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches.

Authors:  H W Murray
Journal:  Int J Infect Dis       Date:  2000       Impact factor: 3.623

2.  Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic.

Authors:  S Sundar; D K More; M K Singh; V P Singh; S Sharma; A Makharia; P C Kumar; H W Murray
Journal:  Clin Infect Dis       Date:  2000-10       Impact factor: 9.079

3.  Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.

Authors:  T K Jha; P Olliaro; C P Thakur; T P Kanyok; B L Singhania; I J Singh; N K Singh; S Akhoury; S Jha
Journal:  BMJ       Date:  1998-04-18

4.  Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.

Authors:  J D Berman; R Badaro; C P Thakur; K M Wasunna; K Behbehani; R Davidson; F Kuzoe; L Pang; K Weerasuriya; A D Bryceson
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

5.  Treatment of visceral leishmaniasis in children with liposomal amphotericin B.

Authors:  L di Martino; R N Davidson; R Giacchino; S Scotti; F Raimondi; E Castagnola; L Tasso; A Cascio; L Gradoni; M Gramiccia; M Pettoello-Mantovani; A D Bryceson
Journal:  J Pediatr       Date:  1997-08       Impact factor: 4.406

6.  Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony.

Authors:  S Sundar; N K Agrawal; P R Sinha; G S Horwith; H W Murray
Journal:  Ann Intern Med       Date:  1997-07-15       Impact factor: 25.391

7.  Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome).

Authors:  R N Davidson; L di Martino; L Gradoni; R Giacchino; G B Gaeta; R Pempinello; S Scotti; A Cascio; E Castagnola; A Maisto; M Gramiccia; D di Caprio; R J Wilkinson; A D Bryceson
Journal:  Clin Infect Dis       Date:  1996-06       Impact factor: 9.079

8.  Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study.

Authors:  C P Thakur; A K Pandey; G P Sinha; S Roy; K Behbehani; P Olliaro
Journal:  Trans R Soc Trop Med Hyg       Date:  1996 May-Jun       Impact factor: 2.184

9.  Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex.

Authors:  S Sundar; A K Goyal; D K More; M K Singh; H W Murray
Journal:  Ann Trop Med Parasitol       Date:  1998-10

10.  Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days.

Authors:  R Dietze; S M Fagundes; E F Brito; E P Milan; T F Feitosa; F A Suassuna; G Fonschiffrey; G Ksionski; J Dember
Journal:  Trans R Soc Trop Med Hyg       Date:  1995 May-Jun       Impact factor: 2.184

View more
  40 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

Review 2.  Leishmaniasis: new approaches to disease control.

Authors:  Clive R Davies; Paul Kaye; Simon L Croft; Shyam Sundar
Journal:  BMJ       Date:  2003-02-15

Review 3.  [Therapy of tropical diseases after returning from travel].

Authors:  G D Burchard; H Sudeck
Journal:  Internist (Berl)       Date:  2003-05       Impact factor: 0.743

4.  Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India.

Authors:  Prabhat K Sinha; Paul Roddy; Pedro Pablo Palma; Alice Kociejowski; María Angeles Lima; Vidya Nand Rabi Das; Jitendra Gupta; Nawin Kumar; Gaurab Mitra; Jean-François Saint-Sauveur; Siju Seena; Manica Balasegaram; Fernando Parreño; Krishna Pandey
Journal:  Am J Trop Med Hyg       Date:  2010-08       Impact factor: 2.345

5.  New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas.

Authors:  Kathryn M Dupnik; Eliana L Nascimento; Joao F Rodrigues-Neto; Tatjana Keesen; Maria Zélia Fernandes; Iraci Duarte; Selma M B Jeronimo
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

Review 6.  Chemotherapeutics of visceral leishmaniasis: present and future developments.

Authors:  Shyam Sundar; Anup Singh
Journal:  Parasitology       Date:  2017-12-07       Impact factor: 3.234

7.  Microscopy and polymerase chain reaction detection of Leishmania chagasi in the pleural and ascitic fluid of a patient with AIDS: Case report and review of diagnosis and therapy of visceral leishmaniasis.

Authors:  Ada Rs Diehl; Rodrigo P Dos Santos; Ricardo Zimmerman; Letícia P Luz; Tanara Weiss; Pedro Jacobson; Luciano Z Goldani
Journal:  Can J Infect Dis Med Microbiol       Date:  2004-07       Impact factor: 2.471

8.  Treatment of visceral leishmaniasis.

Authors:  E M Moore; D N Lockwood
Journal:  J Glob Infect Dis       Date:  2010-05

9.  Liposomal amphotericin B and leishmaniasis: dose and response.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  J Glob Infect Dis       Date:  2010-05

10.  Pharmacotherapeutic options for visceral leishmaniasis-current scenario.

Authors:  Krishna Pandey; Prabhat Kumar Sinha; Vidyanand Ravi Das; Sanjiva Bimal; Shubhankar K Singh; Pradeep Das
Journal:  Clin Med Pathol       Date:  2009-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.